The following is a glossary of a number of the terms and acronyms which can be found within this document:

ABC

Anti-Bribery and Anti-Corruption

AER

Actual Exchange Rate

ANZ

Australia and New Zealand

APM

Alternative Performance Measures

BEPS

Base Erosion Profit Shifting

Bioequivalence

The demonstration that the proposed formulation has the same biological effects as the pioneer product to which it is being compared. This is usually demonstrated by comparing blood concentrations of the active over time, but can be compared using a clinical endpoint (e.g. lowering of a worm count) for drugs that are not absorbed or for which blood levels cannot be determined

bps

Basis Points

CAGR

Compound Annual Growth Rate

CAP

Companion Animal Products

Capex

Capital Expenditure

CDGP

Canine Diabetes Genetics Partnership

CER

Constant Exchange Rate

CMO

Contract Manufacturing Organisation

Code

UK Corporate Governance Code 2018

CRM

Client Relationship Management

CSOP

Company Share Option Plan

CSR

Corporate Social Responsibility

CVMP

Committee for Veterinary Medicinal Products

Dechra Values or Values

Dedication, Enjoyment, Courage, Honesty, Relationships and Ambition

DPM&S

Dechra Pharmaceuticals Manufacturing and Supply

DSC

Dechra Service Center

DVP

Dechra Veterinary Products

DVP EU

Dechra Veterinary Products EU or Dechra Veterinary Products Europe

DVP International

Dechra Veterinary Products International

DVP NA

Dechra Veterinary Products North America

DVP US

Dechra Veterinary Products US

EBIT

Earnings before interest and tax. This is the same as operating profit

EBITDA

Earnings before interest, tax, depreciation and amortisation

EMA

European Medicines Agency

EPS

Earnings Per Share

ERP

Enterprise Resource Planning

ESG

Environmental, Social and Governance

ESPP

Employee Stock Purchase Plan

ETR

Effective Tax Rate

EU Pharmaceuticals

European Pharmaceuticals Segment comprising DVP EU, DVP International and DPM&S

Executive Directors

The Executive Directors of the Company, currently Ian Page, Paul Sandland and Tony Griffin

FAP

Food producing Animal Products

FDA

US Food and Drug Administration

FRC

Financial Reporting Council

FRS

Financial Reporting Standards

FTSE

Companies listed on the London Stock Exchange

FTSE 250/350 Index

An index comprising the 101st to 350th largest companies listed on the London Stock Exchange in terms of their market capitalisation

GAAP

Generally Accepted Accounting Practices

GDPR

General Data Protection Regulation

GHG

Greenhouse Gas

GMP

Good Manufacturing Practices

GRT

Gross Registered Tonnage

GPTW

Great Place To Work

HR

Human Resources

IAS

International Accounting Standards

IFRSs

International Financial Reporting Standards

IT

Information Technology

KPI

Key Performance Indicator

LATAM

Latin America

Leverage

The ratio of Net Debt to underlying EBITDA

LIBOR

The London Inter-Bank Offered Rate

LTA

Lost Time Accident

LTAFR

Lost Time Accident Frequency Rate

LTIP

Long Term Incentive Plan

MAT

Moving Annual Total

MRL

Maximum Residue Limit

Non-Executive Directors

The Non-Executive Directors of the Company, currently Tony Rice, Lisa Bright, Julian Heslop, Lawson Macartney, Ishbel Macpherson and Alison Platt

NA Pharmaceuticals

North American Pharmaceuticals Segment comprising DVP US, Canada and Dechra-Brovel

OECD

The Organisation for Economic Cooperation and Development

Ordinary Shares

An ordinary share of 1 pence in the share capital of the Company

Oracle Programme

Enterprise Resources Planning (ERP) software

PDRA

Dechra’s Product Development and Regulatory Affairs team

PPE

Personal Protective Equipment

POMs

Prescription Only Medicines

Qualifying LTIP Award

Qualifying LTIP Awards comprises a CSOP option and an ordinary nil-cost LTIP award, with the ordinary award scaled back at exercise to take account of any gain made on exercise of the CSOP option

R&D

Research and Development

RCF

Revolving Credit Facility

RIDDOR

Reporting of Injuries, Diseases and Dangerous Occurrences Regulations

Rights Issue

The three for ten rights issue of 20,040,653 shares, details of which are set out in the prospectus of the Company dated 25 April 2012

ROCE

Return On Capital Employed

RPI

Retail Price Index

SASB

Sustainability Accounting Standards Board

SAYE

Save As You Earn Share Scheme

SDG

United Nations Sustainable Development Goals

SET

Senior Executive Team

SG&A

Selling, General and Administrative Expenses

S&OP

Sales & Operations Planning

SPC

Summary of Product Characteristics

TCFD

Taskforce for Climate-related Financial Disclosures

TGA

Therapeutic Goods Administration

TSR

Total Shareholder Return